Current laboratory methods for comprehensive thrombophilia status require large blood volumes and long turn-around times. We demonstrate the feasibility of performing thrombophilia panel testing of enzymatic functional assays on a microfluidic cartridge using low sample volume.
anemia and a need for blood transfusions. Moreover, the time-to-result for a full thrombophilia test panel is prolonged, particularly in rural settings where access to testing facilities is limited. As a result, adherence to guidelines for thrombophilia panel testing is poor and small-volume sample testing has been identified as a high priority by pediatric specialists. 5 Digital microfluidic technology is based upon the rapid manipulation of discrete droplets by electrical control of their surface tension (electrowetting). 6, 7 This technique can be utilized to transport nanoliter sized droplets using surface energy gradients established by activating a pattern of control electrodes along any path of contiguous electrodes on the printed circuit board of a disposable cartridge. In addition to the transport of droplets, other basic digital microfluidic operations such as merging, splitting, mixing, and dispensing of droplets can be performed simply by varying the patterns of voltage activation. 8 The digital microfluidic platform automates assay runs, allows multiple assays to be performed simultaneously, minimizes sample volume (5 to 50 μL compared to the current standard of 2 to 10 mL), performs precise metering of reaction volumes, shortens testing time, and is low cost and portable, which allows for near-patient testing even in rural settings.
The digital microfluidic platform has previously been used for a variety of biological applications such as colorimetric enzyme assays (glucose), fluorometric enzyme assays (lysosomal enzymes), real-time PCR, and immunoassays, including immunoassays for the critical hypercoagulability factors antithrombin III (ATIII), protein C (PC), protein S, factor VIII (FVIII) and anti-cardiolipin antibodies. 9, 10 However, the platform has not been used to perform enzymatic functional assays for thrombophilia testing, which are a significant component of the thrombophilia panel. Here, we describe the translation of functional assays for ATIII, PC, plasminogen, and FVIII onto a digital microfluidic platform. This study demonstrates the feasibility of performing a comprehensive thrombophilia test panel on a digital microfluidic cartridge through comparison with standard microtiter plate techniques. Results obtained on the microfluidic platform were comparable to traditional microtiter plate assays.
Materials and Methods

Reagents
In-vitro diagnostic chromogenic test kits for ATIII, PC, Plasminogen, and FVIII were obtained from Aniara Corp.
(West Chester, OH, USA). Fluorescent substrates were obtained from Bachem (Bubendorf, Switzerland). Activators and reconstituted, pooled calibration plasma were obtained from Aniara Corp.
Patient Sample Collection and Processing
The requirement for informed consent was waived as de-identified and discarded samples were obtained from the core laboratory at Boston Children's Hospital (BCH). The 
Figure 1
Assay schematics and structures of the custom synthesized fluorogenic substrates for ATIII, PC, Plasminogen, and FVIII. For all assays, activator solutions [Factor Xa (excess) for ATIII, Protac (enzyme extract from snake venom) for PC, Streptokinase + excess fibrinogen for Plasminogen, or Factor IX + Factor Xa for FVIII] were added to plasma samples. After incubation, factor-activator complexes specifically cleave their respective substrates, releasing 7-Amino-4-methylcoumarin (AMC), which was detected by excitation 360/emission 460 nm. Fluorophore generation is directly proportional to the functionality of all factors except for ATIII, where there is an inverse relationship between chromophore generation and activity.
protocol for obtaining discarded specimens was approved by the BCH Institutional Review Board/Committee on Clinical Investigations. This study used discarded whole blood samples (n = 10) collected in sodium citrate-coated tubes (3.2%). Platelet poor plasma was obtained by centrifuging whole blood samples at 300 g for 15 min at 4°C; plasma samples were stored at -80 o C until analysis. Samples were tested on both the microtiter plate and digital microfluidic platforms to establish correlations. The operator for each assay was blinded to the results of any previous testing.
Standard Microtiter Plate Assays
Standard microtiter plate assays were analyzed using a FLUOstar Omega microplate reader (BMG Lab Tech; Cary, NC, USA). In-vitro diagnostic chromogenic test kits (Aniara Corp.) were used for the quantitative determination of coagulation factor function for ATIII, PC, Plasminogen, and FVIII. Chromogenic tests for ATIII, FVIII, Plasminogen, and PC function were initiated by activating the plasma samples with Factor Xa (FXa; excess), Factor IX + FXa, Streptokinase + excess fibrinogen, and Protac (enzyme extract from snake venom), respectively, following incubation times described by the kit manufacturer (Aniara Corp). The factor-activator complexes specifically cleave their respective substrates, releasing para-nitroaniline, which creates a chromophore with peak absorbance at 405 nm. Chromophore generation is directly proportional to the functionality of all factors except for ATIII, for which there is an inverse relationship between chromophore generation and activity.
Microfluidic On-Cartridge Assays
On-cartridge assays were performed using an automated digital microfluidic platform and cartridge (Baebies, Inc; Durham, NC). 9, 11 The desktop instrument contains an embedded computer, a thermal deck, a stationary magnet and a detector for both fluorometric and absorbance measurements. All 4 enzymatic functional assays were individually performed on the cartridge.
To develop the on-cartridge assays, the standard microtiter plate functional assays were modified for performance on the digital microfluidic platform. Whereas the gold standard assays use chromogenic substrates, on-cartridge assays were modified for fluorescence detection using customized fluorometric substrates. The following substrates were used: Boc-IIe-Glu-Gly-Arg-AMC (cleavage by FXa, ATIII, and FVIII); Boc-Val-Leu-Lys-AMC (cleavage by plasmin-like streptokinase-Plasminogen); and Boc-Leu-Ser-Thr-Arg-AMC (cleavage by Protac-PC). All fluorescence substrates and activators were diluted in PBS + 0.05% Tween-20 ( Figure 1 ).
Plasma samples were diluted in PBS plus 0.05% tween 20 (pH 7.4 to 7.6) at dilutions 1:64 for ATIII, 1:16 for Plasminogen and FVIII, and 1:2 for Protein C followed by serial dilutions (1:2) to establish linear response ranges ( Table 1) . Because droplet-based microfluidics inherently generates binary dilution levels, these dilutions are binary (factors of 2) approximations of the dilutions suggested for optimal linearity in the original manufacturer's chromogenic-based assay kits. The digital microfluidic instrument software was programmed to mix standards/samples + activators followed by incubation times of 1 min for ATIII and plasminogen, 3 min for FVIII, and 10 min for PC assays.
To perform the cartridge assays, all reagents, activators, and samples were loaded on to the cartridge reservoirs (summarized in Table 1 ) and all subsequent liquid manipulations were performed automatically. Samples were first dispensed and mixed with specific activators. Following incubation, the substrates for ATIII, PC, plasminogen, and FVIII were mixed with the activated samples and fluorescence was measured at 360 nm excitation/460 nm emission wavelengths at the detection electrode. All reagents were dispensed and mixed in a 1:1:1 ratio and all reaction steps were performed at 37°C. Data were exported and analyzed using the same software that was used for the microtiter plate assays (GraphPad Prism 7). The summary of functional assay parameters for each test is shown in Table 1 . Standard curves for ATIII, PC, plasminogen, and FVIII were developed by diluting plasma calibrator samples in PBS + 0.05% Tween 20 (pH 7.4 to 7.6), with the previously described initial dilutions followed by 2 (1:2) serial dilutions, for a total of 3 plasma dilutions and a buffer-only blank ( Table 1) . Assays were performed in triplicate. Reproducibility and limits of detection (LoD) were established for each assay.
Limit of detection (LOD):
The mean signal plus 3 standard deviations of at least 10 blank samples subjected to the assay protocol on-cartridge was measured and interpolated into the calibration curve to obtain the LOD for each of the four analytes. Percent function for each assay was detected with 95% certainty were determined as the LOD.
Inter-assay variation was assessed by running the identical protocol in triplicates. High, medium, and low concentrations of the analytes were spiked in plasma and each concentration was run independently on three separate cartridges. Reference curves were used to determine the function of each analyte. The variation was calculated and expressed as coefficient of variance (%CV) for each analyte function.
Statistical Analysis
Calibration curves based on the pooled calibrant plasma were generated for each of the coagulation factors to evaluate factor activity of unknown samples (GraphPad Prism 7). Briefly, the optimized plasma calibrator dilution for each factor was assigned 100% activity. Fluorescence levels were recorded at each of the dilutions of the plasma calibrant in PBS, representing lower activity levels. 
Figure 2
On-cartridge standard curves for various functional assays are displayed for A, antithrombin III (ATIII); B, Protein C (PC); C, plasminogen; D, Factor VIII (FVIII). All results are displayed as a percent of normal function (determined by calibrator plasma).
and standard microtiter plate assays was performed using discarded plasma specimens by Bland-Altman analysis (GraphPad Prism 7).
Results
Each individual functional assay (ATIII, PC, Plasminogen, and FVIII) was successfully performed on the digital microfluidic cartridge. All assays were sufficiently robust, as demonstrated through reproducibility, limit of detection, and method comparison studies. Standard curves were established for each of the factors on cartridge using pooled calibrator plasma ( Figure 2) . Subsequently, the correlation between on-cartridge results and gold standard microtiter plate assay results was determined using de-identified clinical samples. Reliability and precision metrics were also determined.
The sample volume required for on-cartridge assays was less than 25 μL compared with 2 mL for microtiter plate assays, and time to assay result from sample loading was on average 15 minutes for on-cartridge assays compared with 20 minutes for microtiter plate assays.
Reproducibility
Inter-assay precision was measured for all assays by performing the assay in triplicate on one cartridge per day for five days. The %CV for each function level of each assay was below 20%, indicating that the assays are sufficiently reproducible from cartridge to cartridge and day to day ( Table 2) .
Limit of Detection (LoD)
Nine replicates of blank sample (0% function) for each assay were run on a single cartridge with single samples of 25%, 50%, and 100% function. For ATIII, plasminogen, and PC, a value below 50% function is abnormal. For FVIII, a function of greater than 150% is abnormal. We obtained LoD values of 12% function for ATIII, 5% for PC, 17% for Plasminogen, and 6% for FVIII. Because the LoD on cartridge for all four analytes is below the established limits of >80% precision, on-cartridge methods can sufficiently differentiate between normal and deficient samples ( Table 2 ).
Method Comparison
Method comparison studies for the ATIII, PC, Plasminogen and FVIII assays were performed using 10 de-identified discarded clinical plasma samples. Bland-Altman plots ( Figure 3 ) demonstrate strong agreement with little to no bias (mean difference < 5 in all 4 assays) between microtiter plate absorbance and digital microfluidic fluorescent methods. Some variance was observed between the digital microfluidic method and the gold standard methods for the ATIII assays above 50% function, but the two methods aligned well below 50% function. Factor VIII appeared to exhibit some heteroscedasticity but, in general, is recognized to have higher variability in both methods. PC and plasminogen aligned well across all function levels. The bias and limits of agreement between the 2 methods are shown in Table 3 . The mean bias was less than 5 for all assays, and all values fell within the 95% limits of agreement.
Discussion
This study demonstrates the feasibility of performing automated thrombophilia panel functional assays using small sample volumes. Functional assays for thrombophilia testing were demonstrated for the first time using droplet-based digital microfluidic technology. Both sample volume (25 μL compared with 2 mL) and reagent volume are significantly reduced in the microfluidic assays compared with microtiter plate assays. Although the time-to-result from sample loading was similar in microtiter plate and microfluidic methods (on average, 15 minutes on-cartridge compared with 20 minutes in the microtiter plate), the total time for sample transit and processing is significantly lower for on-cartridge assays (performed near the patient) compared with sendout microtiter plate assays.
The digital microfluidic platform described in this study provides important advantages over current testing methodologies. A smaller volume of blood sample is necessary for each test, and the spatial separation of assays on the cartridge means that multiple assays can be performed using a single sample of blood on a single cartridge. The platform also meets several key requirements for near-patient diagnostic testing. Its small physical footprint allows near patient storage and application, and its ability to provide near-patient testing significantly reduces the overall time to result.
Other types of microfluidic platforms have been utilized for cartridge coagulation assays, but none have addressed functional assays within the thrombophilia panel. 12, 13 Previous studies on the digital microfluidic platform described in this study have been used for immunoassay components of the thrombophilia panel. 14 Because the same cartridge is used for both immunoassays and functional assays, integration of the entire panel on to a single cartridge is feasible. This provides a major advantage over other technologies, which may require aliquots of samples to be distributed to separate external laboratories, thereby increasing the total blood sample volume and cost necessary to complete thrombophilia panel testing. The digital microfluidic platform described in this report is capable of reducing the total volume of phlebotomized blood by reducing the sample volume necessary for each test, as well as reducing the need to draw separate aliquots. An additional advantage of digital microfluidics compared with channel microfluidics is that each assay has the potential to be processed in a spatially discrete reaction that eliminates any cross-reactivity between reagents. 6 For this report, each functional assay was run independently. In the future, all reactions will be multiplexed on a single cartridge, with each reaction independently controlled and optimized, thus reducing cross-reactivity. Bland-Altman comparisons showed minimal variability between microtiter plate results and on-cartridge results. The variability that does exist may be attributed to several factors. For example, microfluidic assays use fluorescent detection, whereas the primary method for microtiter plate assays is absorbance. This difference in detection techniques could contribute to variability.
The thrombophilia testing platform developed herein is particularly attractive for the evaluation of neonatal and pediatric thrombotic conditions, including stroke, peripheral arterial or deep venous thrombosis, and intra-cardiac thrombosis following cardiac surgery. The disadvantages of current testing-the requirement for large volumes of blood samples and long turnaround times-prevent clinicians from utilizing these tests even in appropriate clinical circumstances. The impact of the near patient testing may be greatest in rural and low-volume healthcare settings, where access to full thrombophilia panel testing is restricted by scarce clinical laboratory resources. The digital microfluidic technology described in this report can provide remote or low-volume laboratory facilities with access to complex testing methods, an advantage that is likely to translate into more rapid therapeutic intervention and, in certain clinical scenarios, better patient outcomes. Finally, the reduction in reagent volume, automated droplet manipulations, and eliminated need for shipping result in an overall reduction in cost for the full thrombophilia panel by an order of magnitude.
To complete the comprehensive thrombophilia panel necessary to determine thrombosis risk, testing for certain genetic mutations is also required. Factor V Leiden and prothrombin G20210 mutations are commonly measured abnormalities, necessary for validation of the panel in its entirety, that are not currently available on-cartridge. Future development of gene mutation analysis on the digital microfluidic platform is necessary to complete the thrombophilia panel.
Conclusion
In conclusion, this study describes an automated digital microfluidic platform that can be utilized to test the functional components of the thrombophilia panel on small volumes of plasma with high fidelity, at low-cost, with less labor, and faster turnover times than compared with traditional microtiter plate methods. Further investigation is required to test the application of this novel technology at near patient clinical settings and to expand the array of assays that can be tested on this platform. LM 
